Cabaletta Bio Inc.
CABA
We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA , or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$190M
▼ -44.9% YoY
Op. Margin
–
ROIC
-75.33%
▼ -40.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$163M
▼ -46.3% YoY
Op. Cash Flow (TTM)
-$162M
▼ -48.6% YoY
Net Debt
-$276M
Net Cash Position
Cash & Equiv.
$299M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CABA
Held by ETFs
CABA is in 13 US ETFs. The largest of them, with CABA's weight in each:
Cabaletta Bio (CABA) in two numbers
Questions about Cabaletta Bio
Does Cabaletta Bio (CABA) pay a dividend?
No. Cabaletta Bio (CABA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 30 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CABA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CABA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.